Basic Information

Gene symbol STAT3 Synonyms ADMIO, ADMIO1, APRF, HIES Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description signal transducer and activator of transcription 3

GTO ID GTC0463
Trial ID NCT03794544
Disease Non Small Cell Lung Cancer
Altered gene STAT3
Therapeutic/Target gene Target gene
TherapyASO
Treatment ISIS-STAT3rx|AZD9150|ISIS 481464|IONIS-STAT3-2.5Rx
Co-treatment Durvalumab
PhasePhase2
Recruitment statusCompleted
TitleA Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)
Year2019
CountryCanada|France|Italy|Portugal|Spain|Switzerland|United States
Company sponsorMedImmune LLC
Other ID(s)D9108C00002
Vector information
VectorNo vector was used

Clinical Result

Cohort1: Durvalumab
Administration route intravenous injection
Dosage Durvalumab, 1500 mg, Q4W (on Week 1 Day 1), over a 28-day treatment period
Pts 27
Age Adult, Older_Adult
Outcome Major Pathological Response Rate:Measure Type: Number (95% Confidence Interval):11.1(2.4 to 29.2)
Adverse reactions 0/26(All-cause mortality); 3/26(Cardiac disorders; Infections and infestations; Musculoskeletal and connective tissue disorders)
References PMID: 37707791
Cohort2: Durvalumab_Oleclumab
Administration route intravenous injection
Dosage Durvalumab, 1500 mg, Q4W (on Week 1 Day 1), over a 28-day treatment period|Oleclumab, 3000 mg, Q2W (on Week 1 Day 1 and Week 3 Day 1), over a 28-day treatment period
Pts 21
Age Adult, Older_Adult
Outcome Major Pathological Response Rate:Measure Type: Number (95% Confidence Interval):19.0(5.4 to 41.9)
Adverse reactions 0/21(All-cause mortality); 2/21(Infections and infestations; Metabolism and nutrition disorders; Respiratory, thoracic and mediastinal disorders)
References PMID: 37707791
Cohort3: Durvalumab_Monalizumab
Administration route intravenous injection
Dosage Durvalumab, 1500 mg, Q4W (on Week 1 Day 1), over a 28-day treatment period|Monalizumab, 750 mg, Q2W (on Week 1 Day 1 and Week 3 Day 1), over a 28-day treatment period
Pts 20
Age Adult, Older_Adult
Outcome Major Pathological Response Rate:Measure Type: Number (95% Confidence Interval):30.0(11.9 to 54.3)
Adverse reactions 0/203(All-cause mortality); 1/20(Respiratory, thoracic and mediastinal disorders)
References PMID: 37707791
Cohort4: Durvalumab_Danvatirsen
Administration route intravenous injection
Dosage Durvalumab, 1500 mg, Q4W (on Week 1 Day 1), over a 28-day treatment period|Danvatirsen, 200 mg, on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1), over a 28-day treatment period
Pts 16
Age Adult, Older_Adult
Outcome Major Pathological Response Rate:Measure Type: Number (95% Confidence Interval):31.3(11.0 to 58.7)
Adverse reactions 1/16(All-cause mortality); 5/16(Infections and infestations; Injury, poisoning and procedural complications; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders)
References PMID: 37707791

Relationship Graph

Overview of Knowledge Graph